journal article·2023-07-03

RNA – A choice of potential drug delivery system

Govindharaj Poornima, Karthick Harini, Pragya Pallavi, Pemula Gowtham, Koyeli Girigoswami, Agnishwar Girigoswami

Publisher page

Abstract

There is significant progress in biomedical sciences to use biomaterials as a potential medium for the delivery of pharmacologically active components to diseased cells. This multidisciplinary approach has established that the therapeutic benefit is not directly proportional to the potency of drugs. It is more related to the mode of drug formulations and routes of administration. Biomaterials play a vital role in the formulations of a wide range of pharmaceutical compounds, including antibodies, peptides, drugs, enzymes, and vaccines. Most of these materials have been engineered to release therapeutics for an extended period to overcome the limitations of conventional therapies. This review has initially discussed a brief history of different biomaterials in drug delivery and the clinical needs of the same. The latter part describes the strategies to use RNA as a therapeutic molecule to stop the synthesis of disease-causing proteins that are generated by the misregulations.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical Bionanotechnology, Faculty of Allied Health Sciences, Chettinad Hospital & Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai 603103, India

References (93)

Show source-provided references
1. 10.1016/j.trci.2017.10.00510.1016/j.trci.2017.10.005 ↗
2. 10.1080/02652048.2018.145356010.1080/02652048.2018.1453560 ↗
3. 10.1021/acsnano.9b0066110.1021/acsnano.9b00661 ↗
4. 10.1039/D1MA00069A10.1039/D1MA00069A ↗
5. 10.2174/157340131699920090112045810.2174/1573401316999200901120458 ↗
6. 10.1007/978-981-15-5120-8_1710.1007/978-981-15-5120-8_17 ↗
7. 10.1016/j.nanoso.2020.10063610.1016/j.nanoso.2020.100636 ↗
8. 10.1002/adma.20170532810.1002/adma.201705328 ↗
9. 10.3390/molecules2619590510.3390/molecules26195905 ↗
10. 10.1504/IJNT.2011.03717210.1504/IJNT.2011.037172 ↗
11. 10.3390/pharmaceutics1103012910.3390/pharmaceutics11030129 ↗
12. 10.1016/j.drudis.2006.08.00510.1016/j.drudis.2006.08.005 ↗
13. 10.1002/jps.260082100810.1002/jps.2600821008 ↗
14. 10.33263/BRIAC95.32733310.33263/BRIAC95.327333 ↗
15. 10.1016/B978-0-12-813689-8.00015-X10.1016/B978-0-12-813689-8.00015-X ↗
16. 10.1016/j.pharmthera.2012.03.00310.1016/j.pharmthera.2012.03.003 ↗
17. 10.1016/j.mtchem.2018.09.00110.1016/j.mtchem.2018.09.001 ↗
18. 10.1016/j.jconrel.2011.01.02710.1016/j.jconrel.2011.01.027 ↗
19. 10.2147/BTT.S3838710.2147/BTT.S38387 ↗
20. 10.1016/j.envint.2018.01.01110.1016/j.envint.2018.01.011 ↗
21. 10.2174/138161282166615102715184710.2174/1381612821666151027151847 ↗
22. 10.2174/15680090778166226610.2174/156800907781662266 ↗
23. 10.1016/j.jconrel.2013.01.03210.1016/j.jconrel.2013.01.032 ↗
24. 10.1517/13543776.2016.113126710.1517/13543776.2016.1131267 ↗
25. 10.33263/BRIAC104.86086810.33263/BRIAC104.860868 ↗
26. 10.1080/03639045.2018.153949710.1080/03639045.2018.1539497 ↗
27. 10.1038/nrd436310.1038/nrd4363 ↗
28. 10.1208/s12248-015-9814-910.1208/s12248-015-9814-9 ↗
29. 10.2147/IJN.S15754110.2147/IJN.S157541 ↗
30. 10.2217/nnm-2019-015510.2217/nnm-2019-0155 ↗
31. 10.2174/156720181466617082516061710.2174/1567201814666170825160617 ↗
32. 10.1007/s13346-016-0339-210.1007/s13346-016-0339-2 ↗
33. 10.1007/978-3-319-20206-8_910.1007/978-3-319-20206-8_9 ↗
34. 10.1016/j.ejps.2020.10550310.1016/j.ejps.2020.105503 ↗
35. 10.1016/j.jconrel.2020.01.02810.1016/j.jconrel.2020.01.028 ↗
36. 10.33263/BRIAC92.84985210.33263/BRIAC92.849852 ↗
37. 10.1166/asem.2013.142510.1166/asem.2013.1425 ↗
38. 10.2174/156720181666618111911241010.2174/1567201816666181119112410 ↗
39. Costa J. V. · Drug Deliv. Transl. Res. · 2021 · 1
40. 10.1021/acsabm.9b0003910.1021/acsabm.9b00039 ↗
41. 10.2174/221068121099920072811560110.2174/2210681210999200728115601 ↗
42. 10.1016/j.addr.2021.05.02410.1016/j.addr.2021.05.024 ↗
43. 10.1002/adma.20210379010.1002/adma.202103790 ↗
44. 10.1016/j.addr.2021.11391810.1016/j.addr.2021.113918 ↗
45. 10.33263/BRIAC96.43944510.33263/BRIAC96.439445 ↗
46. 10.1002/jbm.b.3355010.1002/jbm.b.33550 ↗
47. 10.33263/BRIAC95.36837310.33263/BRIAC95.368373 ↗
48. Kenawy, S. H.; Khalil, A. M. Advanced ceramics and relevant polymers for environmental and biomedical applications. Biointerface Res. Appl. Chem, 2020, 10, 5747–5754.10.33263/BRIAC104.747754 ↗
49. 10.33263/BRIAC95.22523110.33263/BRIAC95.225231 ↗
50. 10.1007/978-3-030-74330-7_610.1007/978-3-030-74330-7_6 ↗
51. 10.1038/s41586-020-1978-510.1038/s41586-020-1978-5 ↗
52. 10.3389/fbioe.2019.0013110.3389/fbioe.2019.00131 ↗
53. 10.1101/82551310.1101/825513 ↗
54. 10.1038/s41573-020-0075-710.1038/s41573-020-0075-7 ↗
55. 10.1016/j.drudis.2019.11.00610.1016/j.drudis.2019.11.006 ↗
56. Bandyopadhyay, D.; Lopez, G.; Cantu, S.; Balboa, S.; Garcia, A.; Silva, C.; Valdes, D. Key Enzymes in Cancer: Mechanism of Action and Inhibition With Anticancer Agents. Chemistry Research and Applications (Vol. 2): Organic and Medicinal Chemistry, Chapter 9. 2018. Nova Science Publishers, Inc., Hauppauge, New York, USA.
57. 10.1002/jcph.95710.1002/jcph.957 ↗
58. 10.1186/s13073-017-0450-010.1186/s13073-017-0450-0 ↗
59. 10.15252/emmm.20201324310.15252/emmm.202013243 ↗
60. Rigo F. · Systems Biology of RNA Binding Proteins · 2014 · 303
61. 10.3390/pharmaceutics1309139710.3390/pharmaceutics13091397 ↗
62. 10.1007/PL0000062810.1007/PL00000628 ↗
63. 10.1021/jm701537z10.1021/jm701537z ↗
64. Lönnberg, H. 9 Nucleic Acids as Drugs and Drug Targets 1: Antisense, Splice-Switching, Triplex-Forming and Immune-Stimulatory Oligonucleotides; Berlin: De Gruyter, 2020.; pp. 267–290.10.1515/9783110609295-009 ↗
65. 10.1002/cbdv.20090017710.1002/cbdv.200900177 ↗
66. 10.1093/nar/25.22.442910.1093/nar/25.22.4429 ↗
67. 10.17179/excli2015-29710.17179/excli2015-297 ↗
68. 10.1007/978-1-61779-037-9_510.1007/978-1-61779-037-9_5 ↗
69. 10.1016/j.addr.2013.11.00610.1016/j.addr.2013.11.006 ↗
70. 10.1093/nar/27.4.115210.1093/nar/27.4.1152 ↗
71. 10.1093/nar/gku23510.1093/nar/gku235 ↗
72. 10.1038/nrd274210.1038/nrd2742 ↗
73. 10.1016/j.febslet.2005.08.07910.1016/j.febslet.2005.08.079 ↗
74. 10.1124/pr.120.01955410.1124/pr.120.019554 ↗
75. 10.1021/acs.jmedchem.1c0000310.1021/acs.jmedchem.1c00003 ↗
76. 10.1038/s41392-020-0207-x10.1038/s41392-020-0207-x ↗
77. 10.1016/j.addr.2019.05.00410.1016/j.addr.2019.05.004 ↗
78. 10.1038/s41467-020-14780-510.1038/s41467-020-14780-5 ↗
79. 10.1016/j.jconrel.2018.02.01410.1016/j.jconrel.2018.02.014 ↗
80. 10.1002/cbdv.20110008110.1002/cbdv.201100081 ↗
81. 10.1016/j.ymthe.2020.12.02210.1016/j.ymthe.2020.12.022 ↗
82. 10.1021/acs.bioconjchem.0c0006010.1021/acs.bioconjchem.0c00060 ↗
83. 10.1093/nar/gkt85210.1093/nar/gkt852 ↗
84. 10.3390/molecules2412229710.3390/molecules24122297 ↗
85. 10.1158/1535-7163.MCT-20-059910.1158/1535-7163.MCT-20-0599 ↗
86. 10.1007/s10928-019-09619-610.1007/s10928-019-09619-6 ↗
87. 10.1038/s41587-019-0106-210.1038/s41587-019-0106-2 ↗
88. 10.1093/nar/gkv16210.1093/nar/gkv162 ↗
89. 10.1002/cbic.20160013010.1002/cbic.201600130 ↗
90. 10.1016/j.addr.2015.01.00810.1016/j.addr.2015.01.008 ↗
91. 10.1016/j.drudis.2018.05.03010.1016/j.drudis.2018.05.030 ↗
92. 10.1080/17425255.2021.199238210.1080/17425255.2021.1992382 ↗
93. 10.1089/nat.2018.073610.1089/nat.2018.0736 ↗